Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
Oliveira M, Accordino M, Cervantes A, Gambardella V, Hamilton E, Italiano A, Jhaveri K, Juric D, Kalinsky K, Krop I, Saura C, Schmid P, Turner N, Varga A, Jin Y, Lim S, Royer-Joo S, Shankar N, Schutzman J, Bedard P. Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts. Journal Of Clinical Oncology 2025, 43: 1004-1004. DOI: 10.1200/jco.2025.43.16_suppl.1004.Peer-Reviewed Original ResearchPhase I/IB StudyAdverse eventsPI3K inhibitorsDose interruptionStarting doseLocally advanced/metastatic breast cancerMedian time to onsetRisk factorsMedian time to improvementMedian starting doseHormone receptor-positiveAdvanced/Metastatic Breast CancerEffects of PI3K inhibitorsTime to improvementOn-target side effectsClinical cut-offTime to onsetBaseline risk factorsYears of ageCut-offDose intensityLaboratory glucose valuesReceptor-positiveAdvanced BCPIK3CA mutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply